	US 11,766,478 B2
	Methods for enhancing antigen-specific immune responses
Tzyy-Choou Wu, Stevenson, MD (US); and Chien-Fu Hung, Timonium, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Aug. 28, 2020, as Appl. No. 17/6,224.
Application 17/006,224 is a division of application No. 15/543,806, granted, now 10,799,579, previously published as PCT/US2016/013545, filed on Jan. 15, 2016.
Claims priority of provisional application 62/104,464, filed on Jan. 16, 2015.
Prior Publication US 2020/0390885 A1, Dec. 17, 2020
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 47/64 (2017.01); A61K 33/243 (2019.01); A61K 9/00 (2006.01)

CPC A61K 39/39 (2013.01) [A61K 9/0019 (2013.01); A61K 33/243 (2019.01); A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61K 47/643 (2017.08); A61K 47/646 (2017.08); C07K 14/4721 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); C07K 2319/40 (2013.01); C07K 2319/50 (2013.01)]

9 Claims

1. A method of inducing or enhancing an antigen-specific immune response in a mammal, comprising the steps of:

(a) priming the mammal by administering to the mammal an effective amount of a chemotherapeutic agent; and

(b) boosting the mammal by administering to the mammal an effective amount of an annexin chimeric fusion protein, wherein the annexin chimeric fusion protein comprises Annexin V (annV) fused to at least one immunogenic antigen selected from the group consisting of HPV16 E6, HPV16 E7, modified colon carcinoma antigen AH5, and influenza antigen M1;

thereby inducing or enhancing the antigen-specific immune response.